<DOC>
	<DOCNO>NCT00875550</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy dexmedetomidine ( DEX ) intubate mechanically ventilate pediatric intensive care unit ( PICU ) subject . The key study objective : - To characterize loading maintenance dose DEX age group overall medical condition pediatric subject - To evaluate safety efficacy load maintenance infusion sedation initially intubate mechanically ventilated PICU subject - To explore exposure-response relationship dose DEX clinical measure sedation safety</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Dexmedetomidine ( DEX ) Intubated Mechanically Ventilated Pediatric Intensive Care Unit ( PICU ) Subjects</brief_title>
	<detailed_description>An estimated 175 subject enrol approximately 40 investigative site . Subjects divide two treatment group receive either high dose low dose Dexmedetomidine ( DEX ) . The loading maintenance dos group stratify accord presence absence cardiopulmonary bypass . The level sedation assess use University Michigan Sedation Scale ( UMSS ) . Score 0 ( awake/alert ) ; Score 1 ( sleepy/responds appropriately ) ; Score 2 ( somnolent/arouses light stimulus ) ; Score 3 ( deep sleep/arouses deeper ) ; Score 4 ( unarousable stimulus ) . Based score clinical judgment , additional sedation intravenous midazolam administer accord label . The UMSS score must document administration every midazolam ( MDZ ) dose within five minute dose MDZ . Fentanyl morphine may administer treat pain . Subjects may extubated begin study drug require part study . The efficacy safety parameter monitor include sedation level , heart rate , blood pressure ventilation indicator . Once subject meet site-specified respiratory criterion , undergo tracheal extubation . The dexmedetomidine infusion may continue extubation sedation require post-extubation . The continuous infusion dexmedetomidine must administer minimum 6 hour maximum 24 hour . Sedation level , heart rate , blood pressure , respiratory rate , ventilator setting , SpO2 available transcutaneous carbon dioxide ( TcCO2 ) and/or arterial blood gas ( ABG ) monitor record peri-extubation period .</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Initially intubate mechanically ventilated pediatric subject ( ≥1 month [ birth age correct prematurity ] &lt; 17 year age ) intensive care set . The mean subject intubate may include nasotracheal , endotracheal via tracheotomy . The subject must mechanically ventilated prior commencement study drug . 2 . Anticipated require minimum 6 hour continuous intravenous sedation . 3 . American Society Anesthesiologists ( ASA ) classification 1 , 2 , 3 4 . 4 . A UMSS score 1 , 2 , 3 4 start infusion study drug . 5 . A dose establish subject 's age base upon diagnosis procedure . Status post cardiopulmonary bypass ( s/p CPB ) : Low dose group : Loading dose : 0.2 mcg/kg Maintenance dose titration range ( 0.0250.5 mcg/kg/hr ) High dose group : Loading dose : 0.5 mcg/kg Maintenance dose titration range ( 0.10.7 mcg/kg/hr ) All diagnosis : Low dose group : Loading dose : 0.3 mcg/kg Maintenance dose titration range ( 0.05 0.5mcg/kg/hr ) High dose group : Loading dose : 0.6 mcg/kg Maintenance dose titration range ( 0.2 1.4 mcg/kg/hr ) 6 . If female , subject nonlactating either : 1 . Not childbearing potential , defined premenarche , surgically sterile due bilateral tubal ligation , bilateral oophorectomy , hysterectomy . 2 . Of childbearing potential pregnant time baseline . 7 . Subject 's parent ( ) legal guardian ( ) has/have voluntarily sign date informed consent document approve Institutional Review Board . Assent obtain ageappropriate accord state regulation . 1 . Pediatric subject neurological condition prohibit evaluation sedation opinion investigator ( e.g . increase intracranial pressure extensive brain surgery ) . 2 . The infusion pump minimal capacity accommodate low possible maintenance infusion rate study drug base subject 's weight . 3 . Subjects second degree third degree heart block unless subject pacemaker pacing wire . 4 . Hypotension persist beyond 15 min reassessment prior start study drug : Age 1 month ≤6 month old : systolic blood pressure ( SBP ) &lt; 60 ( millimeter mercury ) mmHg Age &gt; 6 month &lt; 2 yrs old : SBP &lt; 70 mmHg Age &gt; 2 &lt; 12 yr old : SBP &lt; 80 mmHg Age &gt; 12 &lt; 17 yr old : SBP &lt; 90 mmHg 5 . Preexisting bradycardia persists beyond 15 min period reassessment prior start study drug : Age 1 month &lt; 2 month old : HR &lt; 90 beat per min ( bpm ) Age ≥2 month &lt; 12 month old : HR &lt; 80 bpm Age ≥12 month &lt; 2 yrs old : HR &lt; 70 bpm Age ≥ 2 &lt; 12 yr old : HR &lt; 60 bpm Age ≥ 12 &lt; 17 yr old : HR &lt; 50 bpm 6 . Serum glutamic pyruvic transaminase ( SGPT ) /alanine aminotransferase ( ALT ) : 1 month 12 month : &gt; 165 U/L ; &gt; 12 month &lt; 17 year : ≥100 U/L . Note : Subjects may rescreened 6 hr prior study drug infusion ( include subject undergoing cardiac surgery CPB ) . 7 . Subjects know allergy dexmedetomidine , MDZ , morphine fentanyl . 8 . Requirement medication DEX , midazolam , morphine fentanyl sedation pain control . 9 . Subjects immobility form neuromuscular disease , paralysis administration neuromuscular block agent , spinal cord injury T5 , subject muscle weakness form congenital systemic medical illness etiology . Note : subject receive NMB agent intraoperatively must , Investigator 's opinion , free residual neuromuscular blockade prior dose study drug . 10 . Subjects receive another investigational drug device within past 30 day . 11 . Subjects receive DEX previous investigational trial within previous 12 week . 12 . Subjects , opinion investigator , condition risk DEX would expect outweigh benefit ( e.g . cardiogenic shock &gt; 2 vasopressor ) . 13 . Subjects require alpha2 agonists/antagonists list within 48 hrs prior baseline . Alpha2 Agonists : Xylazine* , Clonidine ( Catapres , Dixarit ) , Guanfacine ( Tenex ) , Guanabenz ( Wytensin ) , Mivazerol , Guanadrel ( Hylorel ) , Guanethidine ( Ismelin ) Methyldopa ( Aldomet ) . * Xylazine veterinary product , abuse potentIal human . Alpha2 Antagonists : Corynanthine , Phenoxybenzamine ( Dibenzyline ) , Phentolamine ( Regitine , Rogitine ) , Tolazoline ( Priscoline ) , Yohimbine , Rauwolscine , Idazoxan , Reserpine ( Serpasil ) Mirtazapine ( Remeron , Remeron Soltab ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Intubated mechanically ventilated PICU subject</keyword>
</DOC>